Aspire Biopharma Holdings Inc. has announced the filing of an omnibus patent application with the U.S. Patent and Trademark Office for its innovative sublingual drug delivery platform. The proprietary technology, which has not yet been presented at scientific conferences, is designed to enhance the pharmacokinetic performance of active pharmaceutical ingredients (APIs) by enabling rapid absorption through sublingual blood vessels. Key features of the platform include faster onset of action, reduced drug-food and drug-drug interactions, lower risk of gastrointestinal irritation, and ease of administration, particularly in emergency situations. Aspire believes this advancement could significantly improve the efficacy and safety of a wide range of medications.